Figure 4
Figure 4. PU-H71 leads to the loss of the vFLIP-IKKγ signaling complex. (A) BC3 cells were treated with 2 µM PU-H71 for the time course indicated and subjected to immunoblot analysis. Treatment resulted in decrease of vFLIP, IKKγ, phospho-Akt, and total Akt. This result is representative of at least 4 independent experiments. (B) TIVE-LTC (KSHV+) cells were treated with 2 µM PU-H71 for 48 hours, followed by immunoblot with the indicated antibodies. Results are representative of three independent experiments. (C) BC3-NF-κB-luc reporter cells were treated with 2 µM PU-H71, and luciferase assays performed at the indicated time points. Results shown are the average of 3 independent experiments.

PU-H71 leads to the loss of the vFLIP-IKKγ signaling complex. (A) BC3 cells were treated with 2 µM PU-H71 for the time course indicated and subjected to immunoblot analysis. Treatment resulted in decrease of vFLIP, IKKγ, phospho-Akt, and total Akt. This result is representative of at least 4 independent experiments. (B) TIVE-LTC (KSHV+) cells were treated with 2 µM PU-H71 for 48 hours, followed by immunoblot with the indicated antibodies. Results are representative of three independent experiments. (C) BC3-NF-κB-luc reporter cells were treated with 2 µM PU-H71, and luciferase assays performed at the indicated time points. Results shown are the average of 3 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal